Renad N Alyautdin

List of Publications by Year
in descending order

62	3,784	430874	214800
papers	citations	18 h-index	47 g-index

63	63	63	4138
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier. Journal of Drug Targeting, 2002, 10, 317-325.	4.4	738
2	Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Research, 1995, 674, 171-174.	2.2	517
3	Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharmaceutical Research, 2003, 20, 409-416.	3.5	404
4	Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1246-1253.	2.5	325
5	Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharmaceutical Research, 1997, 14, 325-328.	3.5	321
6	Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80â€“coated polybutylcyanoacrylate nanoparticles: Anin situbrain perfusion study. Journal of Microencapsulation, 1998, 15, 67-74.	2.8	254
7	Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. Journal of Drug Targeting, 2009, 17, 564-574.	4.4	198
8	Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the bloodâ€“brain barrier using surfactant-coated nanoparticles. Journal of Controlled Release, 1997, 49, 81-87.	9.9	168
9	Nanoscale drug delivery systems and the blood–brain barrier. International Journal of Nanomedicine, 2014, 9, 795.	6.7	155
10	Liposomes in topical ophthalmic drug delivery: an update. Drug Delivery, 2016, 23, 1075-1091.	5.7	135
11	Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury. Drug Delivery, 2016, 23, 3520-3528.	5.7	91
12	Application of magnetic liposomes for magnetically guided transport of muscle relaxants and anti-cancer photodynamic drugs. Journal of Magnetism and Magnetic Materials, 2001, 225, 95-100.	2.3	90
13	The porphyrinâ€“fullerene nanoparticles to promote the ATP overproduction in myocardium: 25Mg2+-magnetic isotope effect. European Journal of Medicinal Chemistry, 2009, 44, 1554-1569.	5.5	52
14	Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness. International Journal of Nanomedicine, 2015, 10, 3245.	6.7	42
15	Targeted Delivery Methods for Anticancer Drugs. Cancers, 2022, 14, 622.	3.7	41
16	Antiparkinsonian effect of nerve growth factor adsorbed on polybutylcyanoacrylate nanoparticles coated with polysorbate-80. Bulletin of Experimental Biology and Medicine, 2008, 145, 259-262.	0.8	38
17	Fullerene-based Low Toxic Nanocationite Particles (Porphyrin Adducts of Cyclohexyl Fullerene-C60) to Treat Hypoxia-induced Mitochondrial Dysfunction in Mammalian Heart Muscle. Archives of Medical Research, 2008, 39, 549-559.	3.3	36
18	A mouse model of weight-drop closed head injury: emphasis on cognitive and neurological deficiency. Neural Regeneration Research, 2016, 11, 630.	3.0	27

#	Article	IF	Citations
19	Effects of topically applied tocotrienol on cataractogenesis and lens redox status in galactosemic rats. Molecular Vision, 2014, 20, 822-35.	1.1	17
20	Employment of magnet-susceptible microparticles for the targeting of drugs. Journal of Pharmacy and Pharmacology, 2011, 41, 286-288.	2.4	16
21	Effects of apolipoproteins on dalargin transport across the blood-brain barrier. Bulletin of Experimental Biology and Medicine, 2006, 142, 703-706.	0.8	13
22	NEW PORPHYRIN ADDUCT OF FULLERENE-C₆₀: A PROMISING NANOTOOL FOR MEDICINAL USE IN THE HEART MUSCLE HYPOXIA CASES. International Journal of Nanoscience, 2008, 07, 113-135.	0.7	13
23	Intraocular distribution of topically applied hydrophilic and lipophilic substances in rat eyes. Drug Delivery, 2016, 23, 2765-2771.	5.7	13
24	The Mitochondria Free Iron Content to Limit an Isotope Effect of 25Mg2+ in ATP Synthesis: A caution. Cell Biochemistry and Biophysics, 2013, 66, 417-418.	1.8	11
25	Mechanism of the anticataract effect of liposomal MgT in galactose-fed rats. Molecular Vision, 2016, 22, 734-47.	1.1	7
26	Using Nanoparticles to Target Drugs to the Central Nervous System. , 2000, , .		6
27	Perspectives of the development of pharmaceutical nanotechnology. Russian Journal of General Chemistry, 2012, 82, 519-526.	0.8	5
28	Nanoscale Therapeutic System: Safety Assessment Features. Safety and Risk of Pharmacotherapy, 2019, 7, 127-138.	0.2	5
29	SIGNAL AS A TOOL OF THE PHARMACOVIGILANCE. Safety and Risk of Pharmacotherapy, 2018, 6, 61-67.	0.2	5
30	Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems. Molecules, 2022, 27, 3507.	3.8	5
31	Preparation and evaluation of bioavailability of gatifloxacine-loaded nanoparticles. Moscow University Chemistry Bulletin, 2011, 66, 129-132.	0.6	4
32	Ocular Tissue Distribution of Topically Applied PEGylated and Non-PEGylated Liposomes. Advanced Materials Research, 0, 832, 1-8.	0.3	4
33	Fullereneâ€“Interfaced Porphyrin Ligand in Affinity Chromatography of Membrane Proteins. Chromatographia, 2008, 68, 295-298.	1.3	3
34	The tissue-specific â€œferromagnetic attackâ€•on hyperactivation of ATP synthesis by magnesium-25 in mitochondria. Magnesium Research, 2012, 25, 177-181.	0.5	3
35	Vaccine Safety International Monitoring. Safety and Risk of Pharmacotherapy, 2019, 7, 6-14.	0.2	3
36	Analysis of Factors Influencing the Interchangeability of Antiepileptic Drugs. Pharmaceutical Chemistry Journal, 2016, 50, 181-184.	0.8	2

#	Article	IF	Citations
37	Interchangeability Criteria for Levofloxacin-Based Medicinal Products in the Russian Federation. Pharmaceutical Chemistry Journal, 2017, 50, 684-690.	0.8	2
38	Drug Safety for Children â€" International Monitoring Data for 50 Years. Safety and Risk of Pharmacotherapy, 2019, 7, 57-64.	0.2	2
39	Gastroprotective effect of on ethanol-induced gastric mucosal injury: Histopathological evaluations.. Avicenna Journal of Phytomedicine, 2022, 12, 30-41.	0.2	2
40	Cytotoxic Effect of Paclitaxel Incorporated in Nanoparticles Based on Lactic and Glycolic Acid Copolymer. Bulletin of Experimental Biology and Medicine, 2011, 151, 340-343.	0.8	1
41	Interchangeability Problems of Drugs with Narrow Therapeutic Indices. Pharmaceutical Chemistry Journal, 2017, 51, 722-725.	0.8	1
42	Limits for the Content of Heavy Metals and Arsenic as a Means of Ensuring Safe Use of Herbal Medicinal Products. Safety and Risk of Pharmacotherapy, 2021, 9, 61-68.	0.2	1
43	Optimization of poloxamer 188 concentration as media for nanoparticle dispersion: effect of concentration, nanoparticle size and in vitro penetration through blood brain barrier. International Journal of Pharma and Bio Sciences, 2017, 8, .	0.1	1
44	Identification and Evaluation of Safety Signals of Drugs Currently under Development Using a Limited Data Set. Safety and Risk of Pharmacotherapy, 2019, 7, 216-220.	0.2	1
45	Preparation of a periodic safety update report. Safety and Risk of Pharmacotherapy, 2018, 6, 6-10.	0.2	1
46	Assessment of Pharmacovigilance Reporting in Russia. Safety and Risk of Pharmacotherapy, 2018, 6, 150-154.	0.2	1
47	Adverse Reactions of Drugs Containing Valeriana and Corvalol: Analysis of Spontaneous Reporting. Safety and Risk of Pharmacotherapy, 2018, 6, 162-173.	0.2	1
48	Rate Setting for Labour Costs Related to Pharmacovigilance System Inspections. Safety and Risk of Pharmacotherapy, 2022, 10, 13-18.	0.2	1
49	Russian pharmacovigilance: ways to improve efficiency. Vestnik of Russian Military Medical Academy, 2022, 24, 81-90.	0.3	1
50	Inductively Coupled Plasma-Atomic Emission Spectrometry for the Analysis of Heavy Metals and Arsenic in Tinctures. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products, 2022, 12, 173-182.	0.2	1
51	Effect of leucine-enkephalin on interneuronal transmission of excitation. Bulletin of Experimental Biology and Medicine, 1979, 87, 582-584.	0.8	0
52	Experimental study of magnetically controlled transport of neuromuscular blocking agents diadonium and dipyronium in animals. Bulletin of Experimental Biology and Medicine, 1986, 102, 926-928.	0.8	0
53	Amino Acid Composition of Nephrophyt, a New Complex Plant Preparation and Its Possible Role in Correction of Mercuric Chloride-Induced Acute Renal Failure in Rats. Bulletin of Experimental Biology and Medicine, 2004, 137, 167-170.	0.8	0
54	A fullerene C60-based ligand in a stationary phase for affine chromatography of membrane porphyrin-binding proteins. Russian Journal of Physical Chemistry A, 2008, 82, 1952-1957.	0.6	0

#	Article	IF	Citations
55	Prospects of Using Brain-Derived Neurotrophic Factor for the Treatment of Optic-Nerve Neuropathy (A Review). Pharmaceutical Chemistry Journal, 2015, 48, 699-702.	0.8	0
56	Elaboration of regulatory approaches to managing the risk of the use of biomedical cell products in the Russian Federation. Farmatsiya-Moscow, 2021, 70, 5-14.	0.1	0
57	UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4. Safety and Risk of Pharmacotherapy, 2018, 6, 54-60.	0.2	0
58	Signal Messages in Pediatric Practice. Safety and Risk of Pharmacotherapy, 2018, 6, 180-186.	0.2	0
59	Application of nanoscale polymer colloid carriers for targeted delivery of the brain-derived neurotrophic factor through the blood-brain barrier in experimental parkinsonism. Bulletin of Russian State Medical University, 2019, , 107-112.	0.2	0
60	Comparative Analysis of International Databases of Adverse Drug Reactions. Safety and Risk of Pharmacotherapy, 2020, 8, 134-140.	0.2	0
61	Neuroprotective effect of poly(lactic-co-glycolic acid) nanoparticle-bound brain-derived neurotrophic factor in a permanent middle cerebral artery occlusion model of ischemia in rats. Acta Neurobiologiae Experimentalis, 2020, 80, 1-18.	0.7	0
62	Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety Monitoring. Safety and Risk of Pharmacotherapy, 2022, 10, 110-117.	0.2	0